Florida 7-OH Crackdown

On July 29, 2025, the Food and Drug Administration (FDA) recommended that concentrated synthetic 7-hydroxymitragynine (7-OH) opioid products be classified as a Schedule I substance under the Controlled Substances Act. Following the FDA’s guidance, Florida Attorney General James Uthmeier issued an emergency scheduling order on August 13, 2025, limiting allowable concentrations of 7-OH in Florida. This rule was further updated on August 19 to limit the allowable concentrations of 7-OH to 0.04% by dry weight. This action effectively removes concentrated synthetic 7-OH opioid products from the market while leaving natural leaf kratom unaffected. The updated rule closes a loophole that had previously allowed manufacturers to produce larger tablets under a 1% by total weight threshold. This announcement comes after concentrated 7-OH opioid producers sought to launch a “Florida compliant” product.